Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope: hepatitis c drugs after liver cancer treatment

NCT ID NCT02771405

Disease control Sponsor: National Hepatology & Tropical Medicine Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether interferon-free drug combinations can cure hepatitis C in 150 people who had been successfully treated for liver cancer. Participants took pills like sofosbuvir and ribavirin for 12 weeks. The main goal was to see if the virus stayed undetectable 12 weeks after treatment, and to check for any cancer return.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sofosbuvir, Ribavirin, Simeprevir, Daclatasvir, Ledipasvir
What this could lead to
If successful, this could show that treating hepatitis C after liver cancer treatment reduces cancer recurrence and improves long-term outcomes.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients. There is a risk of virologic failure or cancer recurrence despite treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2016

Finished

Jan 2018

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-70 years old * Confirmed HCV viremia by PCR * CHILD Pugh "A" or "B7,B8" * Confirmed HCC either by laboratory ,imaging or histopathological criteria * Underwent or candidate for curative intervention for HCC (BCLC stage 0 ,A) * Willing to be treated for HCV and signing informed consent Exclusion Criteria: * Patients below 18 or above 70 years old * patients with advanced liver condition "CHILD score ≥ B9" * Patients with advanced HCC status (BCLC≥ B) * Patients with combined HBV ,HIV infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis C are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis C virus infection hepatitis C virus infection hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis C, chronic Hepatocellular carcinoma

Contacts and locations

Locations

  • Amr Maged

    Cairo, 11441, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.